Innoscripta (1INN) Q4 2025 TU earnings summary

Executive summary

• Achieved significant revenue and EBIT growth in 2025, driven by enterprise client wins, product innovation, and operating leverage.

• Maintained strong focus on organizational efficiency, sales quality, and disciplined cost control.

• Expanded enterprise client base and enhanced product offerings, including AI-driven features and international no-code solutions.

• Continued international expansion efforts, targeting new markets with a conservative, organic approach.

• Management remains committed to long-term growth and shareholder value, with founders retaining close to 80% ownership and post-IPO lock-up.

Financial highlights

• Revenue grew to €104 million in 2025, up nearly 60% year-over-year from €65.3 million in 2024.

• EBIT reached €63.6 million, a 67% increase from €38.0 million in 2024, with an EBIT margin of 61.1%.

• Operating/free cash flow improved to €41 million, reflecting better cash collection and shorter payment terms.

• Sales and marketing spend increased to over €19 million, remaining at 18.5%-19% of revenue.

• R&D expenditure nearly doubled to €6.6 million, representing 6.4%-6.6% of revenue.

Outlook and guidance

• Confident in achieving consensus revenue growth of nearly 40% for 2026, supported by new and existing client monetization.

• Plans to provide formal guidance at the annual shareholder meeting and publish final audited results on February 20, 2026.

• Management expects to maintain high margins while investing in international expansion and product development.

• International market entry is expected to accelerate due to platform enhancements.